Skip to main content
OpenTrials
Completed

NCT Number: NCT04844892

Phrenic Nerve Stimulation-Induced Lung ReAeration Trial

The Lungpacer PROTECT Diaphragm Pacing Therapy System (DPTS) is a temporary, percutaneously-placed, transvenous, phrenic nerve-stimulating device intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients. The purpose of the PROTECT DPTS is to improve gas exchange, regional lung ventilation, and hemodynamics, and decrease atelectasis in patients presenting with acute respiratory distress syndrome (ARDS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital La Pitié-Salpêtrière

Paris, 75651, France

About this study

The PIRAT clinical study is intended to assess the feasibility, safety and effectiveness of transvenous phrenic-nerve-stimulating diaphragm pacing on clinical outcomes in mechanically ventilated patients. By delivering electrical stimulation to the phrenic nerves, which in turn causes the diaphragm muscle to contract, the PROTECT DPTS is intended to protect the diaphragm from atrophy and preserve lung mechanics to reduce lung inflammation and injury associated with short-term mechanical ventilation. Sustained lung and diaphragm health during early mechanical ventilation is expected to reduce the risk of comorbidities, improve clinical outcomes such as weaning success, and thereby reduce the number of patients who require prolonged mechanical ventilation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are 18 years or older
  • Have been mechanically ventilated due to moderate ARDS for 48-120h
  • Have a PaO2/FiO2 ratio < 200 and > 100 at the time of screening with PEEP ≥ 5 cmH2O
  • Are expected to remain on mechanical ventilation ≥ 48 hours
  • Are under continuous sedation with Richmond Agitation Sedation Scale (RASS) ≤ -3

Exclusion criteria

  • Septic shock with hemodynamic instability (norepinephrine or epinephrine < 0.5 gamma/kg/min)
  • Catheter access to left subclavian vein deemed impossible
  • Use of neuromuscular blocking agents within last 12 hours
  • Bacteremia within the last 48 hours or uncontrolled source of infection
  • Currently on ECMO
  • Enrolled in any other study of an investigational drug or device, which may affect the outcomes of the current study
  • Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles
  • BMI >45 kg/m2
  • Known or suspected phrenic nerve paralysis
  • Any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer PROTECT DPTS, including neurological pacing/stimulator devices and cardiac pacemakers and defibrillators
  • No affiliation to the French health insurance system
  • Under curatorship
  • Imprisoned
  • Known or suspected to be pregnant or lactating

Treatment and study plan

Lungpacer PROTECT Diaphragm Pacing Therapy

Device

PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.

Other names: Lungpacer PROTECT DPTS

Primary outcomes

  1. Changes in PaO2/FiO2 ratio

    Time frame: Day 1

    The changes in PaO2/FiO2 ratio during each acute standard of care ventilation and acute PROTECT pacing therapy session.

Secondary outcomes

  1. Successful LIVE catheter placement

    Time frame: Day 1

    LIVE Catheter was successfully inserted into the left subclavian vein, positioned in accordance with the LIVE Catheter IFU, and the diaphragm was stimulated.

  2. Alveolar-arterial (A-a) gradient

    Time frame: Day 1

    Alveolar-arterial (A-a) gradient documenting gas exchange during each acute standard of care ventilation and acute PROTECT pacing therapy session.

  3. Cardiac output index

    Time frame: Day 1

    Pulse contour cardiac output index assessed by transpulmonary thermodilution during each acute standard of care ventilation and acute PROTECT pacing therapy session.

  4. Regional lung ventilation

    Time frame: Day 1

    Regional lung ventilation assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.

  5. Regional lung atelectasis

    Time frame: Day 1

    Regional lung atelectasis assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.

  6. Serious adverse events

    Time frame: Day 5

    Occurrence of pneumothorax, significant bleeding and desaturation serious adverse events.

Other outcomes

  1. Days until successful weaning

    Time frame: Day 5

  2. Mortality

    Time frame: Day 5

Sponsors and collaborators

Lead sponsor

Lungpacer Medical Inc.

Industry

Registry information

Official study title

A Protocol Investigating the Impact of Lungpacer PROTECT Diaphragm Pacing Therapy on Gas Exchange, Hemodynamics, Regional Lung Ventilation and Atelectasis in Patients Presenting With Moderate ARDS

Acronym: PIRAT

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 14, 2021
Registry last updated
Oct 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.